Ionis Pharmaceuticals, Inc. develops RNA-targeted medicines and reports news around marketed medicines and a pipeline in neurology, cardiometabolic disease and other high-need areas. Company updates commonly address commercial performance for TRYNGOLZA, financial results, R&D revenue from partnerships, and progress across antisense oligonucleotide programs.
Clinical and regulatory news also covers programs such as olezarsen for severe hypertriglyceridemia, zilganersen for Alexander disease, and partner-developed bepirovirsen for chronic hepatitis B. Governance and investor-relations releases include annual meeting materials, board composition changes, and healthcare conference presentations.
Summary not available.
Summary not available.
Summary not available.
Ionis Pharmaceuticals has announced that its partner Biogen received FDA approval for QALSODY (tofersen) as the first treatment targeting a genetic cause of amyotrophic lateral sclerosis (ALS)/b) associated with the gene mutation. This accelerated approval is based on a significant reduction of the neurofilament light chain, a biomarker linked to neuronal damage in ALS patients treated with QALSODY. The drug is administered via injection and aims to address the severe impact of SOD1 mutations, with ongoing trials to confirm clinical benefits. Notably, QALSODY joins another Ionis-developed drug, SPINRAZA, in tackling rare neurodegenerative diseases. However, approval is contingent on further demonstration of clinical efficacy from ongoing studies.
Ionis Pharmaceuticals announced successful results from its Phase 3 NEURO-TTRansform study for eplontersen, aimed at treating hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The study met all co-primary and secondary endpoints, with a significant reduction of 82% in serum TTR concentration among treated patients compared to an 11% reduction in the placebo group (p0.0001). Eplontersen also halted disease progression and improved quality of life, as measured by neuropathy impairment and quality of life scores. The findings, presented at AAN 2023, highlight eplontersen's potential as a new treatment option for patients with this fatal disease. The FDA has accepted a New Drug Application for eplontersen, with a PDUFA date set for December 22, 2023, while the company plans further regulatory submissions in Europe and beyond.
Ionis Pharmaceuticals has announced a live webcast scheduled for May 3, 2023, at 11:30 a.m. Eastern Time, to discuss its first quarter 2023 financial results. This event will provide insights into the company's financial performance, emphasizing its leadership in RNA-targeted therapies. Ionis has over three decades of experience and currently boasts three marketed medicines alongside a robust late-stage pipeline focused on cardiovascular and neurological treatments. Stakeholders can access the webcast and follow up with a replay through Ionis' investor relations page.
Ionis Pharmaceuticals announced new Phase 1b clinical data for IONIS-MAPTRx (BIIB080), revealing a dose-dependent reduction of tau protein in cerebrospinal fluid (CSF) in early-stage Alzheimer's patients. The study, presented at AD/PD 2023, showed a significant decrease in tau pathology measured by positron emission tomography (PET) at week 25 through week 100. In all dose groups, there was a 60% reduction in baseline CSF tau levels by study's end. The primary focus was on safety, with mild to moderate adverse events reported. The ongoing Phase 2 CELIA study for IONIS-MAPTRx is currently recruiting participants in the U.S.
Ionis Pharmaceuticals (NASDAQ: IONS) announced participation in upcoming investor conferences, enhancing its visibility in the healthcare sector. Notable events include the Guggenheim Virtual Genomic Medicines and Rare Disease Days on April 4, 2023, and the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. A live webcast of the presentations will be available on the Ionis website, with replays accessible within 48 hours.
With over 30 years in RNA-targeted therapy, Ionis is a leader in genetic medicine, possessing three marketed medicines and a strong late-stage pipeline focusing on cardiovascular and neurological conditions.
Ionis Pharmaceuticals reported positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study for eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The study met co-primary endpoints, showing significant reductions in TTR levels and improved neuropathy symptoms and quality of life. Results will be shared at the AAN Annual Meeting in April, with U.S. FDA accepting a New Drug Application for eplontersen, targeting a decision by December 22, 2023. The data indicates eplontersen may fulfill a critical need for new treatments for this severe condition.
Ionis Pharmaceuticals announced a favorable outcome from the FDA's Advisory Committee meeting regarding tofersen, a treatment for SOD1 amyotrophic lateral sclerosis (ALS). The committee voted 9-0 that the evidence suggests a reduction in neurofilament light chain (NfL) levels indicates potential clinical benefits. However, there was mixed support for traditional approval, with 3 in favor, 5 against, and 1 abstention. If approved by the FDA, expected by April 25, 2023, tofersen would be the first treatment targeting a genetic cause of ALS. This represents a significant advancement in ALS therapeutics, as there are currently no genetically targeted treatments available.